celecoxib has been researched along with Lymph Node Metastasis in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer." | 9.51 | Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 9.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 9.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer." | 5.51 | Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 5.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 5.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Zoledronic acid (ZA) 4 mg was administered for six 3-weekly cycles, then 4-weekly for 2 years." | 2.84 | Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. ( Attard, G; Barber, J; Cassoly, E; Clarke, NW; Cross, W; Dearnaley, DP; Gilson, C; Ibrahim, A; James, ND; Jones, RJ; Logue, J; Lydon, A; Mason, MD; Matheson, D; Millman, R; Nikapota, AD; O'Sullivan, JM; Parker, CC; Parmar, MKB; Porfiri, E; Protheroe, A; Rentsch, CA; Ritchie, AWS; Russell, JM; Schiavone, F; Spears, MR; Srihari, NN; Sydes, MR; Thalmann, GN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C, 2017) |
| " As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2." | 1.40 | Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. ( Girish, GV; Lala, PK; Liu, L; Majumder, M; Xin, X, 2014) |
| "Furthermore, breast cancer cells exposed to the involuting mammary microenvironment acquired prolymphangiogenic properties that contributed to peritumor lymphatic expansion, tumor size, invasion, and distant metastases." | 1.40 | Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. ( Betts, CB; Borges, VF; Guo, Q; Jindal, S; Kapoor, P; Lyons, TR; Martinson, HA; Schedin, P, 2014) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | 1.38 | Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib. ( Marschner, N; Zaiss, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Kang, L | 1 |
| Zhang, J | 1 |
| Wu, Z | 1 |
| Wang, H | 2 |
| Huang, M | 1 |
| Lan, P | 1 |
| Wu, X | 1 |
| Wang, C | 1 |
| Cao, W | 1 |
| Hu, J | 1 |
| Huang, Y | 1 |
| Huang, L | 1 |
| Shi, L | 1 |
| Cai, Y | 2 |
| Shen, C | 1 |
| Ling, J | 1 |
| Xie, X | 1 |
| He, X | 1 |
| Dou, R | 1 |
| Zhou, J | 1 |
| Ma, T | 1 |
| Zhang, X | 2 |
| Luo, S | 1 |
| Deng, W | 1 |
| Ling, L | 1 |
| Liu, H | 3 |
| Deng, Y | 1 |
| Majumder, M | 1 |
| Xin, X | 1 |
| Liu, L | 1 |
| Girish, GV | 1 |
| Lala, PK | 1 |
| Lyons, TR | 1 |
| Borges, VF | 1 |
| Betts, CB | 1 |
| Guo, Q | 1 |
| Kapoor, P | 1 |
| Martinson, HA | 1 |
| Jindal, S | 1 |
| Schedin, P | 1 |
| Ogawa, F | 1 |
| Amano, H | 1 |
| Eshima, K | 1 |
| Ito, Y | 1 |
| Matsui, Y | 1 |
| Hosono, K | 1 |
| Kitasato, H | 1 |
| Iyoda, A | 1 |
| Iwabuchi, K | 1 |
| Kumagai, Y | 1 |
| Satoh, Y | 1 |
| Narumiya, S | 1 |
| Majima, M | 1 |
| Botti, G | 1 |
| Fratangelo, F | 1 |
| Cerrone, M | 1 |
| Liguori, G | 1 |
| Cantile, M | 1 |
| Anniciello, AM | 1 |
| Scala, S | 1 |
| D'Alterio, C | 1 |
| Trimarco, C | 1 |
| Ianaro, A | 1 |
| Cirino, G | 1 |
| Caracò, C | 1 |
| Colombino, M | 1 |
| Palmieri, G | 1 |
| Pepe, S | 1 |
| Ascierto, PA | 1 |
| Sabbatino, F | 1 |
| Scognamiglio, G | 1 |
| Mason, MD | 1 |
| Clarke, NW | 1 |
| James, ND | 1 |
| Dearnaley, DP | 1 |
| Spears, MR | 1 |
| Ritchie, AWS | 1 |
| Attard, G | 1 |
| Cross, W | 1 |
| Jones, RJ | 1 |
| Parker, CC | 1 |
| Russell, JM | 1 |
| Thalmann, GN | 1 |
| Schiavone, F | 1 |
| Cassoly, E | 1 |
| Matheson, D | 1 |
| Millman, R | 1 |
| Rentsch, CA | 1 |
| Barber, J | 1 |
| Gilson, C | 1 |
| Ibrahim, A | 1 |
| Logue, J | 1 |
| Lydon, A | 1 |
| Nikapota, AD | 1 |
| O'Sullivan, JM | 1 |
| Porfiri, E | 1 |
| Protheroe, A | 1 |
| Srihari, NN | 1 |
| Tsang, D | 1 |
| Wagstaff, J | 1 |
| Wallace, J | 1 |
| Walmsley, C | 1 |
| Parmar, MKB | 1 |
| Sydes, MR | 1 |
| Falandry, C | 1 |
| Debled, M | 1 |
| Bachelot, T | 1 |
| Delozier, T | 1 |
| Crétin, J | 1 |
| Romestaing, P | 1 |
| Mille, D | 1 |
| You, B | 1 |
| Mauriac, L | 1 |
| Pujade-Lauraine, E | 1 |
| Freyer, G | 1 |
| Yang, Y | 2 |
| Xiao, J | 2 |
| Lv, Y | 2 |
| Liu, Y | 2 |
| Yang, H | 2 |
| Zhao, L | 2 |
| Lustberg, MB | 1 |
| Povoski, SP | 1 |
| Zhao, W | 1 |
| Ziegler, RM | 1 |
| Sugimoto, Y | 1 |
| Ruppert, AS | 1 |
| Lehman, AM | 1 |
| Shiels, DR | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Layman, RM | 1 |
| Brueggemeier, RW | 1 |
| Shapiro, CL | 1 |
| Ninomiya, I | 1 |
| Nagai, N | 1 |
| Oyama, K | 1 |
| Hayashi, H | 1 |
| Tajima, H | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Marschner, N | 1 |
| Zaiss, M | 1 |
| Diperna, CA | 1 |
| Bart, RD | 1 |
| Sievers, EM | 1 |
| Ma, Y | 1 |
| Starnes, VA | 1 |
| Bremner, RM | 1 |
| Chen, Z | 1 |
| Li, M | 1 |
| Wang, Z | 1 |
| Wieand, HS | 1 |
| Grandis, JR | 1 |
| Shin, DM | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable Non-metastatic Colorectal Cancer Patients With Mismatch Repair-deficient or Microsatellite Instability-high[NCT03926338] | Phase 1/Phase 2 | 69 participants (Anticipated) | Interventional | 2019-05-10 | Recruiting | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for celecoxib and Lymph Node Metastasis
| Article | Year |
|---|---|
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cele | 2022 |
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cele | 2017 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase I | 2009 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular | 2011 |
11 other studies available for celecoxib and Lymph Node Metastasis
| Article | Year |
|---|---|
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Celecoxib; Cell Line, Tumor; | 2014 |
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Female | 2014 |
Prostanoid induces premetastatic niche in regional lymph nodes.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Celecoxib; Cell Line, Tumor; Chemokine CXCL12 | 2014 |
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Topics: B7-H1 Antigen; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Down-Regulation; G | 2017 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2009 |
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2010 |
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cycloo | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone | 2012 |
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase | 2004 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |